β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis.

MLA

Aspatwar, Ashok, et al. “β-CA-Specific Inhibitor Dithiocarbamate Fc14–584B: A Novel Antimycobacterial Agent with Potential to Treat Drug-Resistant Tuberculosis.” Journal of Enzyme Inhibition & Medicinal Chemistry, vol. 32, no. 1, Jan. 2017, pp. 832–40. EBSCOhost, https://doi.org/10.1080/14756366.2017.1332056.

APA

Aspatwar, A., Hammarén, M., Koskinen, S., Luukinen, B., Barker, H., Carta, F., Supuran, C. T., Parikka, M., & Parkkila, S. (2017). β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. Journal of Enzyme Inhibition & Medicinal Chemistry, 32(1), 832–840. https://doi.org/10.1080/14756366.2017.1332056

Chicago

Aspatwar, Ashok, Milka Hammarén, Sanni Koskinen, Bruno Luukinen, Harlan Barker, Fabrizio Carta, Claudiu T. Supuran, Mataleena Parikka, and Seppo Parkkila. 2017. “β-CA-Specific Inhibitor Dithiocarbamate Fc14–584B: A Novel Antimycobacterial Agent with Potential to Treat Drug-Resistant Tuberculosis.” Journal of Enzyme Inhibition & Medicinal Chemistry 32 (1): 832–40. doi:10.1080/14756366.2017.1332056.